A federal jury found Amgen liable for violating antitrust and tort laws. Elsewhere, Allogene and Kyverna trimmed staff and ...

Morning! Today we start with some breaking newss: Novo Nordisk’s CEO is stepping down. We also discuss a new, tailored CRISPR treatment for an infant with a deadly disease, how Amgen owes Regeneron ...

Regeneron (REGN) wins $400M in damages as jury finds Amgen (AMGN) violated antitrust laws by promoting its heart drug Repatha ...

DZ Bank has significantly reduced its holdings in Regeneron Pharmaceuticals, offloading 74.4% of its shares in Q4. Despite ...

Shares of Regeneron Pharmaceuticals Inc. REGN advanced 2.39% to $584.99 Thursday, on what proved to be an all-around positive ...

Regeneron Pharmaceuticals won $406.8 million in damages for a lawsuit claiming Amgen violated antitrust and tort laws. A jury in a Delaware court found that Amgen violated certain laws, and gave ...

Fintel reports that on May 14, 2025, Citigroup upgraded their outlook for Regeneron Pharmaceuticals (NasdaqGS:REGN) from ...

Uncertainty around pharma tariffs on and pricing policies under the Trump has much of the sector guessing what will happen ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...

Regeneron earns a buy rating with strong profit margins, low debt, and growth potential. Discover why shares may see a 39% ...

Deutsche Bank AG boosted its stake in Regeneron Pharmaceuticals by nearly 22% in Q4, now holding 539,269 shares valued at ...

We recently published a list of 10 Worst Blue Chip Stocks to Buy. In this article, we are going to take a look at where ...